Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
about
Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma.Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.Proteomic profiling of the cancer cell secretome: informing clinical research.Current Role of Dacomitinib in Head and Neck Cancer.Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.The evolving landscape in advanced penile cancer.First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.Increasing aggressiveness of patient-derived xenograft models of cervix carcinoma during serial transplantation.
P2860
Q26765429-F475D4F7-A54D-47D8-AC16-269A4256CC67Q27687709-A18C8441-BDA0-4975-844C-F144B0E1BE07Q36500914-F9F3A6BD-E937-4AA1-839A-B56AB054424FQ36689140-C61A0D9B-D901-46A2-BCAD-F12857CAE3A6Q38659528-BB707824-E1BE-4451-BF24-DAFD504FEDF4Q38806115-D4AD7D73-9A76-4B0B-99E9-123359B55BD3Q38854643-F05DF2DA-F745-41F8-B977-5821AF05C182Q39073840-F5EF0A1A-466F-42FF-8B48-ECEA3862B388Q41239578-BCDB987F-DC98-4541-A4B5-47FD88933A32Q42358603-5BDF6EA9-C2A7-4FBE-9C37-97F66EF58190Q48331376-EF3ABD1A-9993-4730-B1DE-7F4E6E54E91AQ48651245-4C3DDC1B-3B88-4EAF-8142-E8EE10FA5490Q55192211-7456990C-40A7-4F93-9751-F7598D550BCE
P2860
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Phase II clinical and explorat ...... ll carcinoma of head and neck.
@en
Phase II clinical and explorat ...... ll carcinoma of head and neck.
@nl
type
label
Phase II clinical and explorat ...... ll carcinoma of head and neck.
@en
Phase II clinical and explorat ...... ll carcinoma of head and neck.
@nl
prefLabel
Phase II clinical and explorat ...... ll carcinoma of head and neck.
@en
Phase II clinical and explorat ...... ll carcinoma of head and neck.
@nl
P2093
P50
P1476
Phase II clinical and explorat ...... ll carcinoma of head and neck.
@en
P2093
Byung Woog Kang
Dok-Hyun Yoon
Eun Chang Choi
Hwan Jung Yun
Hye Ryun Kim
Hyeong Ju Kwon
Ji Hyun Lee
Jin Hee Sohn
Jong-Mu Sun
P304
P356
10.1158/1078-0432.CCR-14-1756
P407
P577
2014-11-25T00:00:00Z